Literature DB >> 9736569

Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.

T J Walsh1, V Yeldandi, M McEvoy, C Gonzalez, S Chanock, A Freifeld, N I Seibel, P O Whitcomb, P Jarosinski, G Boswell, I Bekersky, A Alak, D Buell, J Barret, W Wilson.   

Abstract

The safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) administered for empirical antifungal therapy were evaluated for 36 persistently febrile neutropenic adults receiving cancer chemotherapy and bone marrow transplantation. The protocol was an open-label, sequential-dose-escalation, multidose pharmacokinetic study which enrolled a total of 8 to 12 patients in each of the four dosage cohorts. Each cohort received daily doses of either 1.0, 2.5, 5.0, or 7.5 mg of amphotericin B in the form of AmBisome/kg of body weight. The study population consisted of patients between the ages of 13 and 80 years with neutropenia (absolute neutrophil count, <500/mm3) who were eligible to receive empirical antifungal therapy. Patients were monitored for safety and tolerance by frequent laboratory examinations and the monitoring of infusion-related reactions. Efficacy was assessed by monitoring for the development of invasive fungal infection. The pharmacokinetic parameters of AmBisome were measured as those of amphotericin B by high-performance liquid chromatography. Noncompartmental methods were used to calculate pharmacokinetic parameters. AmBisome administered as a 1-h infusion in this population was well tolerated and was seldom associated with infusion-related toxicity. Infusion-related side effects occurred in 15 (5%) of all 331 infusions, and only two patients (5%) required premedication. Serum creatinine, potassium, and magnesium levels were not significantly changed from baseline in any of the dosage cohorts, and there was no net increase in serum transaminase levels. AmBisome followed a nonlinear dosage relationship that was consistent with reticuloendothelial uptake and redistribution. There were no breakthrough fungal infections during empirical therapy with AmBisome. AmBisome administered to febrile neutropenic patients in this study was well tolerated, was seldom associated with infusion-related toxicity, was characterized by nonlinear saturation kinetics, and was effective in preventing breakthrough fungal infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736569      PMCID: PMC105839     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia.

Authors:  M Arning; A H Heer-Sonderhoff; A Wehmeier; W Schneider
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

2.  Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

Authors:  P Francis; J W Lee; A Hoffman; J Peter; A Francesconi; J Bacher; J Shelhamer; P A Pizzo; T J Walsh
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

3.  Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.

Authors:  J W Lee; M A Amantea; P A Francis; E E Navarro; J Bacher; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.

Authors:  V Heinemann; B Kähny; A Debus; K Wachholz; U Jehn
Journal:  Bone Marrow Transplant       Date:  1994       Impact factor: 5.483

5.  Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.

Authors:  K M Wasan; M G Rosenblum; L Cheung; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

6.  Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths.

Authors:  D Pittet; R P Wenzel
Journal:  Arch Intern Med       Date:  1995-06-12

7.  Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients.

Authors:  W Mills; R Chopra; D C Linch; A H Goldstone
Journal:  Br J Haematol       Date:  1994-04       Impact factor: 6.998

8.  Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone.

Authors:  A Louie; A L Baltch; M A Franke; R P Smith; M A Gordon
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

9.  Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity.

Authors:  W R Perkins; S R Minchey; L T Boni; C E Swenson; M C Popescu; R F Pasternack; A S Janoff
Journal:  Biochim Biophys Acta       Date:  1992-06-30

10.  Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.

Authors:  T T Ng; D W Denning
Journal:  Arch Intern Med       Date:  1995-05-22
View more
  49 in total

1.  Relationship of pharmacokinetically-calculated volumes of distribution to the physiologic distribution of liposomal drugs in tissues: implications for the characterization of liposomal formulations.

Authors:  R M Fielding
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

Review 2.  Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis.

Authors:  S B Girois; F Chapuis; E Decullier; B G P Revol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-02       Impact factor: 3.267

3.  Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.

Authors:  D Andes; N Safdar; K Marchillo; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis.

Authors:  S B Girois; F Chapuis; E Decullier; B G P Revol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

Review 5.  Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Authors:  Shyam Sundar; Neha Agrawal; Bhawana Singh
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-17       Impact factor: 4.481

Review 6.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 7.  Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.

Authors:  João F Lacerda; Carlos Meneses Oliveira
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

8.  Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.

Authors:  E W Van Etten; L E Stearne-Cullen; M ten Kate; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

9.  Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats.

Authors:  I Bekersky; G W Boswell; R Hiles; R M Fielding; D Buell; T J Walsh
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 10.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.